News

Harvard’s ARMMs technology to be commercialized by Vesigen Therapeutics for targeted intracellular delivery of large-molecule drugs

Genetically programmed, living hydrogel material facilitates intestinal wound healing and may lead to a therapy for patients with inflammatory bowel disease

Accelerator-funded research points to potential therapy for heightened touch sensitivity in autism spectrum disorders

Based on innovations from Harvard University and Boston Children's Hospital, Nocion Therapeutics aims to selectively silence pain and itch neurons

Developed through Harvard’s Blavatnik Biomedical Accelerator, innovations could lead to novel cell therapies to treat disease